IL-6是炎症反应中的关键细胞因子，参与包括癌症在内的多种慢性炎症性疾病的发病机制。监测IL-6水平可在临床早期判断疾病类型，对了解疾病进展和预后具有重要意义。研究显示，IL-6通路是维持机体平衡和许多疾病失调的关键途径，靶向IL-6通路的抗体药物成为多种自身免疫病和癌症的创新疗法，并有可能应用于可产生细胞因子风暴的其他疾病。此文针对国内外已上市及在研靶向IL-6/IL-6受体信号通路的单克隆抗体药物的发展进行综述。

IL-6, a critical cytokine in inflammatory response, is involved in the pathogenesis of several chronic inflammatory diseases, including cancer. Monitoring the level of IL-6 can be useful in diagnosing the disease type at early clinical stage, which is of great significance for understanding the disease progression and prognosis. The IL-6 pathway has emerged as a pivotal pathway involved in maintaining homeostasis and dysregulation of many diseases. Antibody targeting the IL-6 pathway has led to innovative therapeutic approaches for autoimmune diseases and cancers. It may also be applied to other diseases that produce cytokine storms. This article reviews monoclonal antibody drugs targeting the IL-6/IL-6 receptor pathway that have been marketed at home and abroad and are under development.